XML 30 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaboration Agreements (Tables)
 9 Months Ended
Sep. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Schedule of Revenues from Collaborations

The following table is a summary of the revenue recognized from the Company’s collaborations for the three and nine months ended September 30, 2017 and 2016:

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2017

 

 

2016

 

 

2017

 

 

2016

 

Teva:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research funding

 

$

14

 

 

$

29

 

 

$

44

 

 

$

87

 

Genentech:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Recognition of upfront payment

 

 

—

 

 

 

—

 

 

 

—

 

 

 

157

 

Research funding

 

 

—

 

 

 

383

 

 

 

—

 

 

 

1,149

 

Milestone payment

 

 

250

 

 

 

—

 

 

 

250

 

 

 

—

 

Total collaboration revenue

 

$

264

 

 

$

412

 

 

$

294

 

 

$

1,393